Decentralized clinical trials still a hot theme in 2022 - Baird

Syneos Health

21/01/2022 12:01

** Virtual or decentralized clinical trials (DCT) will take
center stage in 2022, with COVID-19 acting as catalyst for
adoption of hybrid models of clinical development which combine
traditional tools and processes with decentralized means,
brokerage Baird says
    ** New trial initiations with DCT components jumped from 673
in 2020 to 1,011 in 2021 – and another 1,300 trials will launch
with DCT components in 2022, brokerage says, citing research
firm GlobalData
    ** DCT should foster improved patient experience,
recruitment, retention and overall diversity in clinical trials
- Baird
    ** Strong revenue outlooks of contract research firms
coupled with near-universal expectations for long-term margin
enhancement would suggest that investors need not fret the
impact of DCTs on financials any time soon - brokerage
    ** As a result, brokerage says it expects continued private
investment in DCT service providers like Medable, IPOs as well
as rapid consolidation between DCT oriented specialists and
larger contract drug developers
    
    

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; +91  8061822700;))